GlaxoSmithKline PLC (GSK)

39.30
0.17 0.43
NYSE : Health Care
Prev Close 39.13
Open 39.36
Day Low/High 39.17 / 39.41
52 Wk Low/High 37.20 / 44.54
Volume 1.81M
Avg Volume 2.66M
Exchange NYSE
Shares Outstanding 2.46B
Market Cap 95.11B
EPS 0.50
P/E Ratio 22.23
Div & Yield 1.99 (5.10%)

Latest News

Mylan Badly Needs Help from FDA to Escape its Woes and Deliver These Key Drugs

Mylan Badly Needs Help from FDA to Escape its Woes and Deliver These Key Drugs

Mylan execs have criticized the FDA, which they say has been too slow to approve competitors to complex drugs.

The Stock Market Is Still Tanking Thanks to North Korea Tensions

The Stock Market Is Still Tanking Thanks to North Korea Tensions

Gold nears two-month high as investors take "safety first" approach

European Stocks Set for Mixed Open as Global Markets Stabilize

European Stocks Set for Mixed Open as Global Markets Stabilize

FTSE 100 could see ex-dividend impact at the opening bell.

Biotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring

Biotech Movers: Buzz on Potential Suitors Sends United Therapeutics Stock Soaring

GlaxoSmithKline could be among the suitors for United Therapeutics, the Evening Standard reported.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BA, CAI, CNHI, FFWM, FSV, NEP, NOW, TGI, TRK, TSU, WPG Downgrades: AAT, BLMN, FBR, GSK, HZO, QDEL, VRTX Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Another Day - Another Busy Slate of Earnings

Another Day - Another Busy Slate of Earnings

Ford Motor Co. leads a list of notable earnings reports being released throughout the day on Wednesday

Ford and the Fed - 5 Things You Must Know Before the Market Opens Wednesday

Ford and the Fed - 5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures are marginally higher on Wednesday ahead of an announcement from the Federal Reserve on interest rates.

GSK Stock Falls on Reduced Guidance

GSK Stock Falls on Reduced Guidance

Higher investment in HIV led GSK to cut earnings guidance

GlaxoSmithKline Names Former Walmart Exec as New CTO

GlaxoSmithKline Names Former Walmart Exec as New CTO

GSK is looking to expand its digital platforms.

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

GSK Submits EU Filing For Extended Use Of Relvar Ellipta In Patients With Controlled Asthma On An ICS/LABA Combination

GSK Submits EU Filing For Extended Use Of Relvar Ellipta In Patients With Controlled Asthma On An ICS/LABA Combination

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol,...

China Was Right to Walk Away From Failed U.S. Trade Talks

China Was Right to Walk Away From Failed U.S. Trade Talks

The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.

Hikma Shakes Up U.S. Operations After FDA Disappointment; CEO Said Darwazah to Lead Group

Hikma Shakes Up U.S. Operations After FDA Disappointment; CEO Said Darwazah to Lead Group

Hikma shares were active in London trading Monday after the drugmaker unveiled a reorganization of its U.S. business that includes a change in leadership.

Europe Mixed at Close After Day of Pressure

Europe Mixed at Close After Day of Pressure

Commodity markets, economic growth and the potential for a broad tightening of monetary policy in the developed world over the coming quarters recaptured investors' attention Thursday.

Google and Novartis Back Medicxi's New $300 Million Fund

Google and Novartis Back Medicxi's New $300 Million Fund

Developing a promising drug? This new investment fund is looking to invest in Phase 2 candidates.

Still Waiting for the All-Clear on FANG

Resist the urge to buy; their time will come again.

European Stocks See New Peaks in Volatile Session

European Stocks See New Peaks in Volatile Session

While causing upset among politicians and some business leaders, President Donald Trump's withdrawal of the U.S. from the Paris Agreement helped boost stock prices across the chemicals and automotive sectors.

GlaxoSmithKline Shares Boosted By Renewed Push In HIV Treatment

GlaxoSmithKline Shares Boosted By Renewed Push In HIV Treatment

Glaxo was boosted Friday after its HIV joint-venture filed an application in the U.S. and EU for a new combination tablet, in a continued push for dominance in the field

GlaxoSmithKline Surges to New Highs

GlaxoSmithKline Surges to New Highs

GSK is trading at 2017 highs today as investors continue to aggressively accumulate shares.

European Stocks Mixed on Cocktail of Deal Speculation, Politics and Economic Data

European Stocks Mixed on Cocktail of Deal Speculation, Politics and Economic Data

European stocks were mixed Wednesday as investors responded to a mixture of M&A speculation, economic data and other individual company news.

Bristol-Myers Hookup Boosts Array BioPharma

Bristol-Myers Hookup Boosts Array BioPharma

Arrary reacquired MEK inhibitor in 2015 as part of FTC settlement with Novartis.

European Stocks Fall as Politics Takes Center Stage

European Stocks Fall as Politics Takes Center Stage

European stocks fell Tuesday as politics returned to forefront of investors' minds, with election talk in Italy and the U.K., and renewed transatlantic sabre rattling, all taking centre stage.

GlaxoSmithKline Shares Gain After HIV Treatment Appears To Hold Lead Over Rival Gilead

GlaxoSmithKline Shares Gain After HIV Treatment Appears To Hold Lead Over Rival Gilead

GlaxoSmithKline shares outperformed the market Tuesday after clinical trials data for Gilead's Bictegravir HIV treatment appeared to reduce the threat of a superior rival to GSK's Dolutegravir.

Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential

Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential

A head-to-head showdown in metastatic breast cancer and the Roche APHINITY data are next key events for Puma.

Perrigo, Taro Show Perils of Failure to Branch in Branded Drugs

Perrigo, Taro Show Perils of Failure to Branch in Branded Drugs

The latest earnings from two of the largest generic drug makers show how important it is for generic firms to have their own stable of higher-margin branded products.

Analysts' Actions -- Cloudera, Carvana, Domino's, McKesson and More

Analysts' Actions -- Cloudera, Carvana, Domino's, McKesson and More

Here are Tuesday's top research calls, including new coverage of recent IPOs Cloudera and Carvana, as well as new analyst coverage of Domino's Pizza and an upgrade of McKesson.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BKFS, CWAY, DE, EZPW, GSK, LMNX Downgrades: AMC, ESRT, MYOK, WERN Initiations: None Read on to get TheStreet Quant Ratings' detailed report: